TITLE

GENZYME FILES FOR EUROPEAN APPROVAL OF SYNVISC

PUB. DATE
September 2006
SOURCE
Worldwide Biotech;Sep2006, Vol. 18 Issue 9, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on an application filed by Genzyme Corp. with the European authority to expand the CE mark for Synvisc to include treatment of pain due to osteoarthritis of the ankle and shoulder. The significance of the approval is cited. Synvisc will be one of the viscosupplements available in Europe for the treatment of osteoarthritis pain.
ACCESSION #
22045065

 

Related Articles

  • Genzyme gets European approval for Synvisc-One.  // PharmaWatch: Biotechnology;Feb2008, Vol. 7 Issue 2, p12 

    The article reports on the European approval granted to Genzyme Corp. through a CE mark for Synvisc-One, a treatment for pain relief from osteoarthritis of the knee. According to Genzyme, Synvisc-One will simplify osteoarthritis pain management and provide added patient convenience. The...

  • Genzyme expects Synvisc-One approval delay.  // Medical Device Daily;11/19/2007, Vol. 11 Issue 222, p4 

    The article reports on the delayed approval for Genzyme's next-generation Synvisc-One, a treatment option for osteoarthritis pain management, in the U.S. According to the company, the Food and Drug Administration (FDA) has asked for additional analyses and data regarding the marketing...

  • Genzyme Wins FDA Approval For Renvela.  // Bioworld Week;10/29/2007, Vol. 15 Issue 44, p3 

    The article reports on the approval granted by the U.S. Food & Drug Administration (FDA) for Genzyme Corp.'s Renvela (sevelamer carbonate) in Cambridge, Massachusetts. Renvela is needed for the control of serum phosphorus in patients with chronic kidney disnease (CKD) on dialysis. It binds...

  • Genzyme's Hylastan fizzles; Synvisc-One efforts continue. Osborne, Randall // Medical Device Daily;7/9/2007, Vol. 11 Issue 130, p2 

    The article deals with Genzyme's hylastan and synvisc-one drugs, indicated to relieve osteoarthritis knee pain. While hylastan failed to beat steroids in a pivotal trial study, the company was unmoved as its synvisc-one awaits a pending approval in the U.S. and Europe. Bo Piela of Genzyme...

  • Genzyme's Synvisc-One formula wins FDA marketing clearance. YOFFEE, LYNN // Medical Device Daily;2/27/2009, Vol. 13 Issue 38, p1 

    The article reports on the U.S. Food and Drug Administration's (FDA) approval of Genzyme's Synvisc-One single-injection visco supplement for the treatment of osteoarthritis knee pain. It is the first of its kind approved in the U.S. and is expected to increase the company's current market share...

  • FDA Advisers Back New Version of Genzyme's Knee-Pain Drug. Young, Donna // BioWorld Today;12/11/2008, Vol. 19 Issue 240, p3 

    The article reports on the unanimous vote by a federal panel of advisers in favor of approval of Genzyme Corporation's Synvisc-One, an investigational injectable product intended to relieve pain associated with osteoarthritis of the knee in patients who do not respond to simple analgesics, such...

  • OREXO'S RAPINYL NEARING REGULATORY DECISION IN EUROPE.  // Worldwide Biotech;Nov2007, Vol. 19 Issue 11, p7 

    The article reports that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) is nearing regulatory decision on Rapinyl, a drug for acute pain treatment from Orexo. The first indication of Rapinyl is breakthrough pain in cancer. The drug is based on...

  • FDA Advisers Back New Version of Knee-Pain Drug.  // Bioworld Week;12/15/2008, Vol. 16 Issue 50, p4 

    The article reports on the approval of the new version of knee-pain drug by Genzyme Corp. in the U.S. Synvisc-one, an investigational injectable product intended to relieve pain linked with osteoarthritis of the knee in patients who do not respond to simple analgesics which mentions...

  • Genzyme receives CE marking for single-treatment Synvisc.  // Medical Device Daily;12/21/2007, Vol. 11 Issue 232, p1 

    The article reports that Genzyme received the CE-mark for Synvisc-One as treatment for pain associated with knee osteoarthritis (OA). The company claims that Synvisc-One is Europe's only viscosupplementation product that provides pain relief in a single injection for six months. Genzyme...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics